Glioblastoma Multiforme Giving Smarter Guide

Glioblastoma multiforme (GBM) remains one of the most aggressive and deadly forms of brain cancer. GBM has limited treatment options and a median survival of just 14.6 months. Fewer than 10 percent of patients survive beyond five years, and recurrence typically signals a poor prognosis.

Some patients initially respond to treatment, but there is a pressing need for more effective and less harmful therapies. There are several areas of promising clinical research that could serve as the tipping point toward extending survival in GBM patients and pave the way to a cure.

Glioblastoma Multiforme: A Giving Smarter Guide to Accelerating Research Progress

SPARC conducted a comprehensive landscape analysis of the research, clinical, and funding ecosystem to identify areas of high potential. The effort aims to raise awareness and mobilize strategic medical philanthropy to accelerate the development and translation of promising GBM research into accessible, life-extending solutions.